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ABSTRACT
Phellamurin is a flavanone glycoside that is abundant in the leaves of Phellodendron wilsonii Hayata et Kanehira (Rutaceae). The disposition kinetics of phellamurin metabolites in rat brain was investigated in this study. Doses of 100 mg/kg and 200 mg/kg were orally
administered to rats. At 0.33, 2, 4 and 6 hr after dosing, rats were dissected and the brain concentrations of the aglycone neophellamuretin
were determined by an HPLC method prior to and after hydrolysis with β-glucuronidase. The mobile phase was acetonitrile: H2O (containing 1% acetic acid, 38:62, v/v). Our results indicated that neophellamuretin glucuronide might be able to cross the blood-brain barrier
and its concentration in the brain was dose-dependent at the two doses investigated, whereas the aglycone neophellamuretin was present
in a trace amount in the brain.
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INTRDUCTION
Flavonoids have attracted much attention in recent years
because of their beneficial pharmacological activities including antioxidation(1), free radical scavenging(2), anticancer(3)
as well as antiviral activity(4), and their additional ability to
modulate drug efflux systems(5-8). Phellamurin, 3,4',5,7tetrahydroxy-8-isoprenylflavanone-7-glucoside (Figure 1), is
a flavanone glycoside that is abundant in the leaves of
Phellodendron wilsonii Hayata et Kanehira (Rutaceae) which
is endemic in Taiwan and commonly used in clinical Chinese
medicine(9). In our previous study, the metabolic pharmacokinetics of phellamurin was reported(10). It was found that the
aglycone neophellamuretin accounted for 20% of the exposure of circulating metabolite of phellamurin, whereas
neophellamuretin glucuronides accounted for the other 80%.
The present study attempted to investigate the disposition
kinetics of phellamurin metabolites in rat brain at doses of
100 mg/kg and 200 mg/kg.

Acetonitrile (LC grade) and ethyl acetate (LC grade) were
obtained from Alps (Taipei, Taiwan) and Mallinckrodt Baker,
Inc. (U.S.A). Hesperetin (95%) was purchased from Sigma
Chemical Co. (St. Louis, Mo, U.S.A.). Dimethylacetamide
was obtained from Wako (Osaka, Japan). PEG 400 and
hydrochloric acid were purchased from Merck (Germany).
Milli-Q plus water (Millipore, Bedford, MA, U. S. A.) was
used for all preparations.
II. Instrumentation and HPLC Conditions
The HPLC apparatus included two pumps (LC-10AT,
Shimadzu, Japan), a communication bus module (CBM-10A,
Shimadzu, Japan), a diode array detector (SPD-M10A,

MATERIALS AND METHODS
I. Chemicals
β-Glucosidase (from almonds) and β-glucuronidase
(from Helix pomatia, containing 121,900 units/mL of β-glucuronidase and 4,100 units/mL of sulfatase) were purchased
from Sigma Chemical Co. (St. Louis, Mo, U.S.A.).
* Author for correspondence: Tel: 04-22031028;
Fax: 04-22031028; E-mail:pdlee@mail.cmc.edu.tw

Phellamurin : R = Glucose
Neophellamuretin : R = H
Figure 1. Structures of phellamurin and neophellamuretin.
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Shimadzu, Japan) and CLASS-LC 10/M10A software
(Shimadzu, Japan). The RP-18e column (LiChrospher 100, 5
µ m, 250 × 4 mm) was equipped with a guard column
(LiChrospher 100, 5 µm). The mobile phase was acetonitrile1% acetic acid (38:62) and the flow rate was 1 mL/min with
the detection wavelength set at 287 nm.
III. Preparation of Neophellamuretin
Neophellamuretin standard was obtained from hydrolysis of phellamurin by β-glucosidase. The detailed procedures
had been described in a previous report(10).
IV. Preparation of Calibration Curve
Various concentrations of 50 µL neophellamuretin solution (in MeOH) were spiked into 450 µL brain homogenate
to afford a series of brain standards consisting of 0.1, 0.2, 0.3,
0.6, 1.2, 2.5 and 5.0 µg/mL. To each 500 µL brain homogenate, 200 µL acetate buffer (pH 5) and 5 µL of ascorbic
acid (200 mg/mL) were added, followed by the addition of
750 µL of EtOAc (containing 1.0 µg/mL hesperetin). The
mixture was vortexed for 20 sec and then centrifuged at 9860
× g for 15 min, the EtOAc layer was removed and evaporated to dryness under N-EVAP, then the residue was reconstituted with 160 µL CH3CN, of which 20 µL was subjected to
HPLC analysis.
The peak-area ratios (neophellamuretin to hesperetin) of
brain standards were determined. A calibration curve was
calculated by linear regression of the peak-area ratios against
neophellamuretin concentrations.
V. Validation of Assay Method
The precision and accuracy of the method were assessed
by intra-day and inter-day assays of brain standards.
Recoveries were determined in quartet and calculated based
on the detected concentrations of neophellamuretin in brain
compared to those in Ringer solution.

R instruments, Rockville center, N.Y.). For the assay of free
form neophellamuretin, the process described above for brain
standards was followed. For the assay of neophellamuretin
with its glucuronides/sulfates, brain homogenate samples
(500 µL) were mixed with 50 µL ascorbic acid and 200 µL βglucuronidase (β-glucuronidase 89.4 units/mL, sulfatase 3.3
units/mL in acetate buffer, pH 5), and then incubated anaerobically at 37˚C for 1 hr for hydrolysis as had been previously
determined. The subsequent procedures were identical as for
brain standards.
VIII. Pharmacokinetic Analysis
The elimination constants were calculated by using
WINNONLIN (version 1.1; SCI software, Statistical
Consulting Inc., Apex, NC). The maximum brain concentration (Cmax) and the corresponding time (Tmax) were recorded
as observed.

RESULTS AND DISCUSSION
In this study, an HPLC method was established for the
assay of neophellamuretin in brain. Neophellamuretin was
well separated with hesperetin as the internal standard and
both could be eluted within 20 min. The retention times of
neophellamuretin and internal standard were 15.8 min and
9.2 min, respectively (Figure 2). The regression line was y =
0.321X – 0.005 (r = 0.9999). The good linearity were found
within the ranges of 0.2~5.0 µg/mL. The precision and accuracy for intra-day and inter-day assays were satisfactory, as
shown in Table 1. The LOQ (limit of quantitation) was 0.2
µg/mL and the LOD (limit of detection) was 6.2 ng/mL. The
recoveries of neophellamuretin from brain at concentrations
of 5.0, 1.2 and 0.3 µg/mL were 87.6 ± 2.1%, 86.6 ± 0.8% and
82.9 ± 1.2%, respectively, as shown in Table 2.
1
4

VI. Animals and Drug Administration
Twenty four male Sprague-Dawley rats weighing
between 250 and 350 g were fasted for 12 hr before dosing.
The oral solution of phellamurin (40.0 mg/mL) was prepared
by dissolving in a solvent containing water: PEG 400 :
dimethylacetamide (5:4:1). Rats were administered with
phellamurin at the doses of 100 mg/kg and 200 mg/kg via
gastric gavage. At 0.33, 2, 4 and 6 hr after dosing, triplicate
rats were dissected and the brains were taken, carefully
washed with ice cold Ringer solution and then frozen at
-30˚C for later analysis.

2
2

0

0

VII. Assay of Brain Samples
After thawing, 0.5 g of brain was homogenized with 1.0
mL Ringer solution using TRI-R STIR-R (model S63C, TRI-

5
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Figure 2. HPLC chromatogram of hesperetin as internal standard (1)
and neophellamuretin (1.4 µg/mL) (2) in a brain sample at 20 min after
oral dosing of 200 mg/kg phellamurin to a rat.
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Table 1. Intraday and interday analytical precision and accuracy of neophellamuretin in brain
Conc.
Precision
Intra-day
Inter-day
µg/mL
Mean ± S.D
(C.V.%)
Mean ± S.D.
(C.V.%)
5.0
5.0 ± 0.05
1.0
5.0 ± 0.05
1.0
3.2
2.5 ± 0.09
3.7
2.5
2.5 ± 0.08
5.7
1.3 ± 0.04
3.1
1.2
1.3 ± 0.07
1.6
0.6 ± 0.03
4.6
0.6
0.6 ± 0.01
7.0
0.3 ± 0.01
2.1
0.3
0.3 ± 0.02
0.2
0.2 ± 0.01
9.2
0.2 ± 0.01
7.5
Table 2. Recovery (%) of neophellamuretin from rat brain
5.0 µg/mL
1.2 µg/mL
0.3 µg/mL
1
90.5
85.1
85.2
2
88.8
86.6
81.1
3
83.5
88.0
82.4
Mean ± S.E.
87.6 ± 2.1
86.6 ± 0.8
82.9 ± 1.2

Mean brain concentration-time profiles of neophellamuretin glucuronides after oral administration of phellamurin are shown in Figure 3 for doses of 100 mg/kg and 200
mg/kg. The Tmax occurred at 20 min after dosing, indicating
fast brain distribution of neophellamuretin glucuronides. The
brain concentrations of neophellamuretin glucuronides after
the dose of 200 mg/kg were much higher than those after 100
mg/kg. The Cmax of neophellamuretin glucuronides was 1.7 ±
0.4 µg/g of brain at the dose of 200 mg/kg, whereas that was
only 0.4 ± 0.1 µg/g at the dose of 100 mg/kg, although our
previous study found that there was no significant difference
in serum levels between the administrations of the two
doses(10).
Our previous study indicated that when phellamurin was
administered orally, the parent compound was not detected in
serum, as hydrolysis to neophellamuretin occurred before
absorption. The rate and extent of neophellamuretin absorption were quite good. About 80% of the absorbed neophellamuretin was circulating in plasma as its glucuronides, the
other 20% was in the form of aglycone neophellamuretin(10).
Our present results found that neophellamuretin glucuronides
3
100 mg/kg
200 mg/kg

CONC (µg/g)

2

1

Accuracy
Intra-day
Relative error (%)
0.2
0.9
1.7
–3.0
–8.7
4.3

Inter-day
Relative error (%)
–0.2
0.4
1.2
–0.3
–9.1
3.8

accounted for the majority of the metabolites in brain and
only a trace of neophellamuretin aglycone was detected, but
lower than LOQ. Glucuronides in general are considered as
highly polar metabolites unable to cross the blood-brain barrier. Although it has been discussed that morphine glucuronidation occurred in human brain tissue, the capacity is
very low compared to that of the liver, indicating that morphine glucuronides can penetrate into the brain despite their
high polarity(12). This study also indicated that neophellamuretin glucuronides might be able to cross the blood-brain
barrier. Glucuronides represent metabolites that are not generally inactive and may contribute to drug action either
directly or indirectly(13).
Our previous drug interaction study found that concurrent oral administration of phellamurin significantly
decreased the total exposure of cyclosporin in plasma by
55.7% in rats(14). The pharmacokinetic and statistical analysis indicated that phellamurin markedly decreased the
absorption of cyclosporin. Cyclosporin is a substrate of both
CYP 3A4 and Pgp (P-glycoprotein)(15,16), the product of mdr
(multidrug - resistance) genes. Therefore, the decreased
absorption of cyclosporin could be accounted for by the
induction of CYP3A4 or/and Pgp by phellamurin or its
metabolites. Because phellamurin has been demonstrated to
inhibit the efflux of a Pgp substrate rhodamine 123 in an
everted sac study(14), the major causative agents for the interaction could be in turn explainable by its major metabolites,
neophellamuretin glucuronides which formed very rapidly
with a Tmax at 30 min after oral dosing of phellamurin(10). Pgp
is expressed in various normal human tissues such as small
intestine, kidney, liver and capillary endothelial cells of brain
and testis(17-20), and is a defense mechanism limiting oral
bioavailability and CNS accumulation of drugs (21) .
Therefore, it is suspected that the presence of neophellamuretin glucuronides in brain might induce brain Pgp and
result in limitation of CNS accumulation of other drugs. The
effects of phellamurin metabolites on the metabolizing
enzyme CYP 3A4 and the drug efflux pump Pgp are worthy
of further investigation.
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Figure 3. Mean brain concentration-time profiles of neophellamuretin
glucuronides after oral dosing of 100 mg/kg and 200 mg/kg phellamurin to rats (n=3 for each time point).
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